Difference between revisions of "Deferiprone (Ferriprox)"
Warner-admin (talk | contribs) m (Text replacement - "manufacturer. Instead" to "manufacturer. Instead") |
Warner-admin (talk | contribs) m (Text replacement - "Category:Drug index" to "Category:Drugs") |
||
| Line 15: | Line 15: | ||
<references/> | <references/> | ||
| − | [[Category: | + | [[Category:Drugs]] |
[[Category:Hematology medications]] | [[Category:Hematology medications]] | ||
[[Category:Chelators]] | [[Category:Chelators]] | ||
[[Category:Drugs FDA approved in 2011]] | [[Category:Drugs FDA approved in 2011]] | ||
Revision as of 23:05, 13 June 2018
FDA approved 10/14/2011
General information
Class/mechanism: Iron chelating agent; binds with ferric ions and forms neutral 3:1 (deferiprone:iron) complexes that are stable over a wide range of pH values. Deferiprone has higher binding affinity for iron than other metals such as copper, aluminum, and zinc.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
- Deferiprone (Ferriprox) package insert pages 9-12[1]
- Deferiprone (Ferriprox) patient drug information (UpToDate)[4]